ESTEVE Reports a 5% Increase in Net Revenue and Strengthens Specialized Company Strategy Pharmaceutical company ESTEVE reveals its annual results for 2024, showcasing a 5% net revenue increase alongside a commitment to specialized healthcare solutions.

ESTEVE Reports a 5% Increase in Net Revenue and Strengthens Specialized Company Strategy #Spain #Barcelona #Healthcare_Innovation #Pharma_Growth #ESTEVE

Navamedic Reports Promising Q4 2024 Results and Plans New Product Launches Navamedic ASA sees solid revenue growth and a vibrant pipeline in 2024 despite challenges, projecting continued expansion in the health sector.

Navamedic Reports Promising Q4 2024 Results and Plans New Product Launches #Norway #Oslo #Navamedic_ASA #Pharma_Growth #Eroxon_Launch